Analyst Price Targets — KYMR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 8:25 pm | Judah Frommer | Morgan Stanley | $123.00 | $95.03 | StreetInsider | Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley |
| February 26, 2026 4:56 pm | Brian Abrahams | RBC Capital | $108.00 | $91.87 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital |
| January 27, 2026 9:26 pm | Eliana Merle | Barclays | $133.00 | $72.15 | TheFly | Kymera Therapeutics assumed with an Overweight at Barclays |
| December 16, 2025 12:52 pm | — | RBC Capital | $103.00 | $85.62 | TheFly | Kymera Therapeutics price target raised to $103 from $70 at RBC Capital |
| December 11, 2025 12:35 pm | Sudan Loganathan | Stephens | $110.00 | $89.90 | TheFly | Kymera Therapeutics price target raised to $110 from $65 at Stephens |
| December 11, 2025 11:53 am | — | Mizuho Securities | $120.00 | $89.90 | TheFly | Kymera Therapeutics price target raised to $120 from $81 at Mizuho |
| December 9, 2025 7:31 pm | — | Jefferies | $122.00 | $86.82 | TheFly | Kymera Therapeutics price target raised to $122 from $73 at Jefferies |
| December 9, 2025 1:55 pm | Srikripa Devarakonda | Truist Financial | $116.00 | $86.27 | TheFly | Kymera Therapeutics price target raised to $116 from $80 at Truist |
| December 9, 2025 1:46 pm | Andrew Fein | H.C. Wainwright | $134.00 | $86.87 | TheFly | Kymera Therapeutics price target raised to $134 from $84 at H.C. Wainwright |
| December 9, 2025 1:03 pm | — | Oppenheimer | $120.00 | $85.60 | TheFly | Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer |
Latest News for KYMR
Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million in FY25, reflecting aggressive advancement of KT-621 and KT-579 into mid-stage trials, prioritizing long-term value over near-term profitability. KT-621's Phase 2b trials in atopic dermatitis and eosinophilic asthma are…
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has earned a consensus recommendation of "Buy" from the twenty-two ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nineteen have issued a buy rating and two have given a strong buy rating to
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYMR.
U.S. House Trading
No House trades found for KYMR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.